Prophylaxis News and Research

RSS

New data from PharmAthene's anthrax vaccine program presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C.

5 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

Roche ships additional quantities of Tamiflu oral suspension

Roche announced today that it has begun shipping additional quantities of Tamiflu® (oseltamivir phosphate) oral suspension (liquid).

3 Dec 2009

Infections remain a common problem in ICU patients

An international study that examined the extent of infections in nearly 1,300 intensive care units (ICUs) in 75 countries found that about 50 percent of the patients were considered infected, with infection associated with an increased risk of death in the hospital, according to a study in the December 2 issue of JAMA.

2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Potentially dangerous needlestick injuries often go unreported

Medical students are commonly stuck by needles - putting them at risk of contracting potentially dangerous blood-borne diseases - and many of them fail to report the injuries to hospital authorities, according to a Johns Hopkins study published in the December issue of the journal Academic Medicine.

26 Nov 2009

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. today announced that abstracts from studies of FOLOTYN™ (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

12 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

Eggs sensitivity and flu shot: Doctors' dilemma

"My three year old had a skin breakout we think was due to eggs - is it safe to do a flu shot?" It's a question being asked to every doctor who takes care of kids during flu season. "On the one hand we are concerned about the devastating effects of the new strain of flu, and on the other we aren't sure if a history of eggs sensitivity is enough to hold the shot or spray," said Bobby Q. Lanier, M.D., clinical professor of pediatrics at the University of North Texas HSC in Fort Worth, Texas, and executive medical director of the American College of Allergy, Asthma and Immunology (ACAAI).

6 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

Four abstracts on RSV and influenza prevention in pediatric health to be presented

MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

31 Oct 2009

AAHP updates about the sale of homeopathic medicines to prevent the flu

Recent news articles regarding the scarcity of the "flu shot" (or influenza inoculations) have been widespread. The shortage of the material, due to manufacturing and regulatory issues, has led to increased interest in homeopathic Influenzinum.

29 Oct 2009

AAHP confirms homeopathic medicines for prophylaxis of infectious diseases

Recent news articles regarding Swine Flu H1N1 have been widespread. The virulence of the strain among humans and its implications for pandemic disease in humans may lead to increased interest in homeopathic treatments for Swine Flu H1N1.

29 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

NovaDel Pharma Inc., has entered into a licensing agreement with privately-held Mist Acquisition, LLC to manufacture and commercialize the NitroMist® lingual spray version of nitroglycerine, a widely-prescribed and leading short-acting nitrate for the treatment of angina pectoris.

28 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

Adjuvanted and non-adjuvanted H1N1 vaccines safe for pregnant women, say Canadian experts

After discussion with the Public Health Agency of Canada, and based on the evidence for other adjuvanted vaccines as well as experience around the world to date with the adjuvanted H1N1 vaccine, Canadian experts say that both the adjuvanted and non-adjuvanted H1N1 vaccines are safe for pregnant women.

23 Oct 2009

Prophylaxis News and Research

New data from PharmAthene's anthrax vaccine program presented

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Roche ships additional quantities of Tamiflu oral suspension

Infections remain a common problem in ICU patients

Canadians with hemophilia A can use new treatment option, XYNTHA

Potentially dangerous needlestick injuries often go unreported

Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

Eggs sensitivity and flu shot: Doctors' dilemma

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

ThromboGenics issues business update for the third-quarter of 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Four abstracts on RSV and influenza prevention in pediatric health to be presented

AAHP updates about the sale of homeopathic medicines to prevent the flu

AAHP confirms homeopathic medicines for prophylaxis of infectious diseases

New CCS guidelines and position papers for physicians and nurse practitioners

Recruitment of Phase II trial of TB-402 completed ahead of schedule

NovaDel and Mist Acquisition enter into licensing agreement to manufacture and commercialize NitroMist

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Adjuvanted and non-adjuvanted H1N1 vaccines safe for pregnant women, say Canadian experts

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News